Cytiva and Fida Biosystems collaborate to improve molecular insight for faster drug discovery

Cytiva, a Danaher company and leader in the life sciences industry, and Fida Biosystems, a Danish company specializing in molecular analysis, have joined forces to expand analytical capabilities for protein research.

The collaboration combines Cytiva’s Biacore surface plasmon resonance (SPR) systems with Fidabio’s in-solution Flow-Induced Dispersion Analysis (FIDA) technology, providing both a complementary and an orthogonal approach that gives scientists a more complete picture of molecular interactions. By linking structural details—such as protein size and stability—with precise binding and interaction data, researchers can make faster, more confident decisions earlier in development.

Why it matters:

• Unified insight: SPR and FIDA together provide orthogonal data for a fuller understanding of complex molecules.
• Better decisions, sooner: Accelerates research on challenging targets like bispecific antibodies and degraders.
• Simplified workflows: Adds depth without adding complexity.

Brian Sørensen, CEO, Fida Biosystems, says: “Combining technologies with Cytiva fosters deeper insight, giving researchers greater confidence in their results. This collaboration supports our mission to advance biophysical analysis and empower scientists with faster, more informative data for complex molecular research.”

Tim Bervoets, President, Discovery & Medical, Cytiva, says: “Researchers need to understand how their molecules behave, and they need that insight quickly. Pairing Biacore SPR with FIDA measurements gives them a more complete picture, without adding complexity. It’s a practical step forward that supports confident decisions and keeps workflows moving. In essence, it helps accelerate the researcher’s time to insight.”

Fidabio’s technology provides both complimentary and orthogonal data to the Biacore SPR system’s data, providing critical information on the quality of sample. By combining two methods, researchers can link structural information, such as protein size and stability, with detailed binding and interaction data. This combined view helps accelerate research on complex molecules, including bispecific antibodies and degraders, while also improving confidence in experimental results.

This partnership reflects Cytiva’s and Danaher’s shared mission to advance analytical science, enable confident, data-driven discoveries, and improve lives through innovation.

‍

Cytiva, the drop logo, and Biacore are trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva. FIDA and Fidabio are registered trademarks of Fida Biosystems A/S.

About Fida Biosystems

Fidabio is a leading innovator in biophysical analysis, delivering in-solution biophysical technology that advances research productivity. Its FIDA platform supports the new wave of drug modalities and targets and enables high double-digit increase of through-put on of established workflows accelerating progress from discovery through development, and opening the space of in-lab creativity thanks to native, crude-sample assays.

Media contact

Brian Sørensen
brian@fidabio.com

About Cytiva

At Cytiva, a Danaher company, our mission is to advance and accelerate the development of therapeutics. With 15 000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma and contract manufacturers. Learn more at cytiva.com

Media contact

James McGarry
James.Mcgarry@cytiva.com

‍